CliffBio
biologic

Spevigo

spesolimab-sbzo

Loss of exclusivityMay 2037projected — 12-year biologic exclusivity estimate
CompanyLEO Pharma A/S

Drug detail

Brand nameSpevigo
Active ingredientspesolimab-sbzo
Strength300MG/2ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2025
Marketing statusRx

More from LEO Pharma A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Spevigo patent cliff — loss of exclusivity May 2037 | CliffBio